Market Place
Sourcing Support
Paratek Ph 2b Data Shows Omadacycline’s Potential in NTM Treatment
15 Nov 2024 //
EXPRESSPHARMA
Paratek Completes U.S. Onshoring for NUZYRA Domestic Supply
14 Nov 2024 //
GLOBENEWSWIRE
Paratek Pharma Positive Phase 2b Omadacycline NTM Data
08 Nov 2024 //
GLOBENEWSWIRE
Paratek Announces Presentation of Studies of Nuzyra at IDWeek 2024
14 Oct 2024 //
GLOBENEWSWIRE
Paratek Completes 5-Year NUZYRA® Surveillance Study
31 Jul 2024 //
GLOBENEWSWIRE
Paratek Reports Positive Data For NUZYRA In Bacterial Pneumonia Study
18 Jul 2024 //
GLOBENEWSWIRE
Paratek Showing NUZYRA, Preclinical Data At ESCMID Global 2024
18 Apr 2024 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA
05 Mar 2024 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel
16 Jan 2024 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in Drug List
13 Dec 2023 //
GLOBENEWSWIRE
Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
05 Oct 2023 //
GLOBENEWSWIRE
Novo Holdings closes $462 million acquisition of Paratek Pharmaceuticals
22 Sep 2023 //
REUTERS
Gurnet Point Capital and Novo Complete Acquisition of Paratek Pharmaceuticals
21 Sep 2023 //
GLOBENEWSWIRE
Glass Lewis Recommends Paratek Stockholders Vote FOR Acquisition by Gurnet Point
12 Sep 2023 //
GLOBENEWSWIRE
Paratek Pharma Files Definitive Proxy Statement and Letter to Stockholders
02 Aug 2023 //
GLOBENEWSWIRE
Paratek Announces Modification of BARDA Contract to Develop NUZYRA
10 Jul 2023 //
GLOBENEWSWIRE
Paratek`s $462M sale under threat from investor NexPoint
28 Jun 2023 //
FIERCE PHARMA
EMA COMP Recommends +ve Opinion on Orphan Medicinal Product Desig. for NUZYRA
27 Jun 2023 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter
27 Jun 2023 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Presenting New Data from NUZYRA
12 Jun 2023 //
GLOBENEWSWIRE
Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings
06 Jun 2023 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million
09 May 2023 //
GLOBENEWSWIRE
Paratek Pharmaceuticals to Report Financial Results for 1Q 2023 on May 9
01 May 2023 //
GLOBENEWSWIRE
Paratek Presenting Data from NUZYRA and Investigator-Initiated Research Programs
10 Apr 2023 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
16 Mar 2023 //
GLOBENEWSWIRE
Paratek to Report Fourth Quarter and Full Year 2022 Financial Results
08 Mar 2023 //
GLOBENEWSWIRE
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01 Mar 2023 //
GLOBENEWSWIRE
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01 Feb 2023 //
GLOBENEWSWIRE
Paratek Announces Inclusion of NUZYRA (omadacycline) in China`s NRDL
18 Jan 2023 //
GLOBENEWSWIRE
Paratek Receives $36.4 M Milestone Payment NUZYRA (omadacycline)
05 Jan 2023 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent DOB
20 Dec 2022 //
GLOBENEWSWIRE
Paratek Pharma Announces Positive Top Line Data from Pilot Efficacy Study
19 Dec 2022 //
GLOBENEWSWIRE
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01 Dec 2022 //
GLOBENEWSWIRE
Paratek Pharmaceuticals to Present at Annual Evercore ISI HealthCONx Conference
21 Nov 2022 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million
03 Nov 2022 //
GLOBENEWSWIRE
Paratek to Present at the Credit Suisse 31st Annual Healthcare Conference
01 Nov 2022 //
GLOBENEWSWIRE
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01 Nov 2022 //
GLOBENEWSWIRE
Paratek Announces Milestone Towards Creating U.S. Supply Chain for NUZYRA
31 Oct 2022 //
GLOBENEWSWIRE
Paratek Achieves Milestone Creating U.S. Mfg. Supply Chain for NUZYRA
31 Oct 2022 //
CONTRACTPHARMA
Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3
25 Oct 2022 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline)
13 Oct 2022 //
GLOBENEWSWIRE
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
03 Oct 2022 //
GLOBENEWSWIRE
Paratek to Host Investor Update on the Global Opportunity in Non-Tuberculous
26 Sep 2022 //
GLOBENEWSWIRE
Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global
01 Sep 2022 //
GLOBENEWSWIRE
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01 Sep 2022 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million
03 Aug 2022 //
GLOBENEWSWIRE
Paratek Pharma to Report Second Quarter 2022 Financial Results
25 Jul 2022 //
GLOBENEWSWIRE
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01 Jul 2022 //
GLOBENEWSWIRE
Paratek`s NUZYRA Receives FDA FTD for Pulmonary NTM Disease Caused by MAC & MAB
21 Jun 2022 //
GLOBENEWSWIRE
Paratek Pharmaceuticals to Present at the Jefferies 2022 Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01 Jun 2022 //
GLOBENEWSWIRE
Paratek Pharmaceuticals to Present at the H.C. Wainwright Conference
16 May 2022 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million
04 May 2022 //
GLOBENEWSWIRE
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
02 May 2022 //
GLOBENEWSWIRE
Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results
26 Apr 2022 //
GLOBENEWSWIRE
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01 Apr 2022 //
GLOBENEWSWIRE
Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million
14 Mar 2022 //
GLOBENEWSWIRE
Paratek Pharma Shows Data on NUZYRA in Pulmonary Mycobacterium avium complex
08 Mar 2022 //
GLOBENEWSWIRE
Paratek Pharma to Report Q4 and Full Year 2021 Financial Results on March 14
02 Mar 2022 //
GLOBENEWSWIRE
